It’s not a single catalyst and the catalyst was a normal one that was undermined by the sale of the idea by a fake journalist that the trial would never be approved or commercial. Of course actual revenue and approval change that assessment. Your false notion that no matter what the news, it will always be bad not only is against the history of the stock, for instance after data lock and then Flaskworks buy, which sent the stock to $2.51 from lows down to .14, but it makes no sense. Your comparison also made no sense because in the instance of Roche, which has billions in revenue, a small ancillary approval for a small or even moderately sized drug only in the UK of course would not move the percentage of new income to raise the stock a lot. Here you’re going from all cost to likely a real revenue. But yeah, they might also want to see NICE approval as well.
But the mere fact of a world class regulatory approval changes the false narrative that the “trial failed” and as I have seen before with Adam Feuerstein, that tends to draw in a whole new class of investors and volume.
It would necessarily foreshadow expectations of approvals by the EMA, FDA and all various treaty partners with the MHRA in the Commonwealth and beyond.
News 
Market Data 
Discover 
AI
